Almac Discovery Showcases its Deubiquitinase Drug Discovery Expertise at the American Association of Cancer Research Annual Meeting in Atlanta
March 18, 2019
Craigavon, N.I., UK, 18 Mar 2019 – Almac Discovery, a biopharmaceutical company focused on discovering and identifying innovative therapeutics for the treatment of cancer, today announced it will present on its research into the field of deubiquitinase mediated protein degradation and homeostasis at the upcoming American Association of Cancer Research (AACR) Meeting in Atlanta, Georgia from 29 March to 3 April 2019.
The current interest in protein homeostasis and quality control as a therapeutic strategy has highlighted the importance of protein ubiquitination as a post-translational modification. Deubiquitinating enzymes (DUBs) are proteases that catalyse the de-ubiquitination of protein substrates and as such offer an attractive way to regulate protein homeostasis. Furthermore, since ubiquitination also controls a plethora of regulatory functions beyond direct degradation, inhibition of DUBs provides additional opportunities to manipulate critical cellular processes.
Almac Discovery was one of the first companies to identify high affinity, selective inhibitors of USP7 and has subsequently built on that foundation to develop capabilities across the whole target class by developing its Ubi-Plex® platform.
At this year’s American Association of Cancer Research Annual meeting Almac Discovery will be presenting at both the Educational and Scientific sessions on this rapidly growing field.
The presentations will be made by Almac Discovery’s Professor Tim Harrison, VP Discovery Chemistry and Dr Xavier Jacq, VP Biology and their individual schedules are outlined below:
Educational Oral Presentation
Title: Discovery and development of USP7 inhibitors
Presenting Author: Professor Tim Harrison
Session: Chemistry to the Clinic: Part 1: Lead Optimization in Cancer Drug Discovery
Location: Room A311 – Georgia World Congress Centre
Date and Time: Saturday Mar 30, 2019 8:30 AM – 8:55 AM
Scientific Oral Presentation
Title: Targeting the ubiquitin-proteasome system by small molecule inhibition of the DUBome
Presenting Author: Dr Xavier Jacq
Session: Minisymposium: Late-Breaking Research 1
Location: Room A402 – Georgia World Congress Centre
Date and Time: Sunday Mar 31 2019 – 3:20 PM – 3:35 PM
Permanent Abstract Number: LB-049
Poster Presentation
Title: Discovery and development of first-in-class orally bioavailable USP19 inhibitors
Presenting Author: Dr Xavier Jacq
Session: Late-Breaking Research: Molecular and Cellular Biology / Genetics 1
Abstract Number: 19-LB-7905-AACR
Location: Section 42 – Georgia World Congress Centre
Date and Time: Monday 1 April 2019 – 8:00 AM – 12:00 PM
Should you wish to meet with the Almac Discovery Team during AACR please contact Martin Wiles, VP Business Development & Licensing – [email protected].
END
About Almac Discovery
Almac Discovery is a research driven oncology company dedicated to the discovery and development of novel and innovative approaches to the treatment of cancer. Almac Discovery focuses on the discovery to preclinical stage seeking to licence programmes early with a pharmaceutical partner for further development.
For more information, please visit almacgroup.com/discovery or e-mail [email protected]
Share
